HIV infection in adolescents: Difference between revisions
(→Dosing) |
(→Dosing) |
||
| Line 8: | Line 8: | ||
*Many ARV medications (e.g., [[abacavir]], [[emtricitabine]], [[lamivudine]], [[tenofovir]], and some [[protease inhibitors]] [PIs]) are administered to children at higher weight- or surface area-based doses than would be predicted by direct scaling of adult doses, based upon reported PK data indicating more rapid drug clearance in children. | *Many ARV medications (e.g., [[abacavir]], [[emtricitabine]], [[lamivudine]], [[tenofovir]], and some [[protease inhibitors]] [PIs]) are administered to children at higher weight- or surface area-based doses than would be predicted by direct scaling of adult doses, based upon reported PK data indicating more rapid drug clearance in children. | ||
*Continued use of these pediatric weight- or surface area-based doses as a child grows during adolescence can result in medication doses that are higher than the usual adult doses. | *Continued use of these pediatric weight- or surface area-based doses as a child grows during adolescence can result in medication doses that are higher than the usual adult doses. | ||
*Many factors may affect the transition from pediatric to adult doses. In addition to toxicity, pill burden, adherence, and virologic and immunologic parameters, factors may include social determinants, such as housing, family support, employment, and recent discharge from the foster care system. | |||
==Reference== | ==Reference== | ||
Revision as of 19:36, 4 June 2012
|
AIDS Microchapters |
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
HIV infection in adolescents On the Web |
|
American Roentgen Ray Society Images of HIV infection in adolescents |
|
Risk calculators and risk factors for HIV infection in adolescents |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
An increasing number of HIV-infected children who acquired HIV infection through perinatal transmission are now surviving into adolescence. They generally have had a long clinical course and extensive ARV treatment history.[1] Adolescents with behaviorally acquired infection (i.e., infection acquired via sexual activity or intravenous substance use) generally follow a clinical course similar to that in adults. Because behaviorally infected adolescents are at an early stage of HIV infection, they are potential candidates for early intervention and treatment.
Treatment
Dosing
- Many ARV medications (e.g., abacavir, emtricitabine, lamivudine, tenofovir, and some protease inhibitors [PIs]) are administered to children at higher weight- or surface area-based doses than would be predicted by direct scaling of adult doses, based upon reported PK data indicating more rapid drug clearance in children.
- Continued use of these pediatric weight- or surface area-based doses as a child grows during adolescence can result in medication doses that are higher than the usual adult doses.
- Many factors may affect the transition from pediatric to adult doses. In addition to toxicity, pill burden, adherence, and virologic and immunologic parameters, factors may include social determinants, such as housing, family support, employment, and recent discharge from the foster care system.
Reference
- ↑ Van Dyke RB, Patel K, Siberry GK, Burchett SK, Spector SA, Chernoff MC, Read JS, Mofenson LM, Seage GR (2011). "Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes". Journal of Acquired Immune Deficiency Syndromes (1999). 57 (2): 165–73. doi:10.1097/QAI.0b013e318215c7b1. PMID 21407086. Retrieved 2012-06-04. Unknown parameter
|month=ignored (help)